Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...
Large-cap public M&A is a hard business to break into, but Paul Hastings feels its build, along with the arrival of Schiele, ...
Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...
JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.
He recently served as Senior Vice President, Head of Global Regulatory and Access Solutions at Cerevel Therapeutics (Cerevel) ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
announces that it is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for violations of the securities laws and ...
Emraclidine was an experimental treatment for schizophrenia and Alzheimer's that AbbVie obtained through its acquisition of Cerevel Therapeutics, along with other experimental drugs such as ...
Kojin Therapeutics, a startup attempting to develop new treatments using programmed cell death, left last month’s JP Morgan Healthcare Conference in a bind.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback